Medicovestor raised $3.16 million to advance ADoBind MC001, an FDA-designated orphan drug antibody-drug conjugate for the treatment of pancreatic cancer, a rare and highly aggressive malignancy with a five-year survival rate under 10%.
Medicovestor raised $3.16 million to advance ADoBind MC001, an FDA-designated orphan drug antibody-drug conjugate for the treatment of pancreatic cancer, a rare and highly aggressive malignancy with a five-year survival rate under 10%.